Metrics as of 10/13/2026, 06:45 PM (Berlin time), refresh in progress.
Lakefront Biotherapeutics Stock
Lakefront Biotherapeutics N.V.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Belgium
- CEO
- Henry O. Gosebruch
- Employees
- 452
- Market cap
- $2 B
- IPO
- 05/05/2005
Lakefront Biotherapeutics N.V., formerly Galapagos NV, is a biotechnology company in the healthcare sector headquartered in Mechelen, Belgium. The company focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Lakefront Biotherapeutics stock: price history
1D
-0.1%
1W
+0.6%
1M
+8.6%
6M
+2.1%
YTD
-8.6%
1Y
-12.3%
2Y
+1.1%
5Y
-44.1%
10Y
-55.2%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~10% stronger price swings than usual
Ask the agents about Lakefront Biotherapeutics
Analyst assessment of Lakefront Biotherapeutics
PRICE TARGET LOW
US$26.00
CONSENSUS
US$35.50
MEDIAN
US$35.50
PRICE TARGET HIGH
US$45.00
0
STRONG BUY
1
BUY
1
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 23/09/2026
Lakefront Biotherapeutics stock metrics
P/E
3.56
P/B
0.53
EV/EBITDA
4.79
RETURN ON EQUITY
0.1%
NET MARGIN
17.4%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
74.6%
FLOAT SHARES
49,189,615
AVG. DAILY VOLUME (30D)
321,890
Comparable stocks
Frequently asked questions about Lakefront Biotherapeutics stock
What does Lakefront Biotherapeutics do?
Lakefront Biotherapeutics N.V. is a company in the Healthcare sector, Biotechnology industry, headquartered in Belgium.
The CEO is Henry O. Gosebruch, the company employs around 452 people.
The IPO was on 05/05/2005; the stock trades on NASDAQ under the ticker LKFT.
What do analysts say about Lakefront Biotherapeutics stock?
2 analysts rate the stock, the consensus is Buy (as of 23/09/2026).
The average price target is US$35.50, ranging from US$26.00 to US$45.00, with a median of US$35.50.
This is an external assessment, not a statement by Market Jury.
When does Lakefront Biotherapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 10% stronger than usual.
Does Lakefront Biotherapeutics pay a dividend?
No, Lakefront Biotherapeutics currently does not pay a dividend.
Which stocks are comparable to Lakefront Biotherapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Lakefront Biotherapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Lakefront Biotherapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.